Losartan Potassium Tablet
Product Images NDC 62207-742

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 62207-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules India Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-30s-label (100mg 30s Label)

Losartan Potassium Tablets USP 100 mg oral tablets label showing NDC 62207-743-54. The label indicates 30 tablets per package, manufactured by Granules India Limited in Hyderabad, India, and distributed by Granules Pharmaceuticals Inc. in Chantilly, VA. Storage instructions and dosage note to see package insert are included.*

FDA Label Image

25mg-30s-label (25mg 30s Label)

Losartan Potassium Tablets, USP 25 mg oral tablets label. The container holds 30 tablets. Manufactured by Granules India Limited in Hyderabad, India, and distributed by Granules Pharmaceuticals Inc., Chantilly, VA. The label includes storage instructions and a barcode.*

FDA Label Image

50mg-30s-label (50mg 30s Label)

Losartan Potassium Tablets USP label showing 50 mg strength in a tablet dosage form. The label states each tablet contains 50 mg of losartan potassium and indicates the package contains 30 tablets. It is manufactured by Granules India Limited, Hyderabad, India, and distributed by Granules Pharmaceuticals Inc., Chantilly, VA. Storage instructions and barcode are also present.*

FDA Label Image

Fig-1 (Fig 1)

A line graph comparing the percentage of patients with primary endpoint events over a 66-month study period between Atenolol (dotted line) and COZAAR (solid line). The graph shows adjusted risk reduction data with a p-value of 0.021.*

FDA Label Image

Fig-2 (Fig 2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study duration of 66 months for Atenolol and Cozaar. The x-axis represents study months, and the y-axis shows the percentage of patients affected, indicating a lower stroke rate for Cozaar compared to Atenolol.*

FDA Label Image

Fig-3 (Fig 3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' displaying comparative hazard ratios with 95% confidence intervals for COZAAR versus Atenolol. The graph includes data on primary composite events and stroke events (fatal/non-fatal) across various demographics such as age, gender, race, ischemic heart status (ISH), diabetes, and history of cardiovascular disease (CVD). Symbols on the plot are proportional to sample size, and the chart includes notes defining subgroup composition and adjustments.*

FDA Label Image

Fig-4 (Fig 4)

A line graph comparing the percentage of patients with an event over a 48-month period for COZAAR versus placebo. The graph shows a lower event rate in the COZAAR group with a calculated risk reduction of 16.1% and a p-value of 0.022, indicating statistical significance.*

FDA Label Image

Losartan-structure (Losartan Structure)

Chemical structure of Losartan Potassium, illustrating its molecular components including chlorinated imidazole and biphenyl tetrazole groups along with a potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.